OBJECTIVES: To estimate the lifetime prevalence of four sexually transmitted infections (STIs) and to identify correlates of these infections among patients seeking care for a substance use disorder at a specialized DeAddictions Unit in southern India. METHODS: Consecutive inpatients (n=361; 98% male; M age=36.7 years) admitted to DeAddictions Unit of the National Institute of Mental Health and Neuro Sciences in Bangalore, India, participated in a structured interview to obtain demographic, psychiatric, sexual behavior, and substance use data; each patient also provided a blood sample for serologic testing for HIV, chlamydia, syphilis, and hepatitis B. RESULTS: One-quarter of all patients tested positive for at least one STI. Lifetime seroprevalence rates were 12.9% for syphilis, 10.3% for chlamydia, 3.1% for hepatitis B, and 1.1% for HIV. Analyses did not reveal any consistent pattern of associations between STI status and sociodemographic, psychiatric, and sexual behavioral characteristics. CONCLUSIONS: All patients should receive a comprehensive sexual assessment during standard care; for those patients who report risky sexual practices, we recommend voluntary counseling and testing for STIs. Although we do not recommend universal testing for STIs at this time, this should be revisited based upon national surveillance data.
OBJECTIVES: To estimate the lifetime prevalence of four sexually transmitted infections (STIs) and to identify correlates of these infections among patients seeking care for a substance use disorder at a specialized DeAddictions Unit in southern India. METHODS: Consecutive inpatients (n=361; 98% male; M age=36.7 years) admitted to DeAddictions Unit of the National Institute of Mental Health and Neuro Sciences in Bangalore, India, participated in a structured interview to obtain demographic, psychiatric, sexual behavior, and substance use data; each patient also provided a blood sample for serologic testing for HIV, chlamydia, syphilis, and hepatitis B. RESULTS: One-quarter of all patients tested positive for at least one STI. Lifetime seroprevalence rates were 12.9% for syphilis, 10.3% for chlamydia, 3.1% for hepatitis B, and 1.1% for HIV. Analyses did not reveal any consistent pattern of associations between STI status and sociodemographic, psychiatric, and sexual behavioral characteristics. CONCLUSIONS: All patients should receive a comprehensive sexual assessment during standard care; for those patients who report risky sexual practices, we recommend voluntary counseling and testing for STIs. Although we do not recommend universal testing for STIs at this time, this should be revisited based upon national surveillance data.
Authors: L H Bachmann; I Lewis; R Allen; J R Schwebke; L C Leviton; H A Siegal; E W Hook Journal: Am J Public Health Date: 2000-10 Impact factor: 9.308
Authors: Jane M Liebschutz; Erin P Finley; Phillip G Braslins; Demian Christiansen; Nicholas J Horton; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2003-05-01 Impact factor: 4.492
Authors: Catherine S Todd; Abdul Nasir; Mohammad Raza Stanekzai; Abdullah M S Abed; Steffanie A Strathdee; Christian T Bautista; Paul T Scott; Boulos A Botros; Jeffrey Tjaden Journal: Sex Transm Dis Date: 2010-11 Impact factor: 2.830
Authors: Hind A Beydoun; Jessica Dail; Hala Tamim; Bethrand Ugwu; May A Beydoun Journal: J Womens Health (Larchmt) Date: 2010-10-15 Impact factor: 2.681
Authors: Lara S Coffin; Ashley Newberry; Holly Hagan; Charles M Cleland; Don C Des Jarlais; David C Perlman Journal: Int J Drug Policy Date: 2009-04-09